Saitn John, Canada Clinical Trials

A listing of Saitn John, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery

cancer chemotherapy
lung carcinoma
durvalumab
Research Site
 (1.2 away) Contact site
  • 102 views
  • 21 Jul, 2021
  • +245 other locations
Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.

durvalumab
lung carcinoma
Research site
 (1.2 away) Contact site
  • 0 views
  • 21 Jul, 2021
  • +186 other locations
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS) Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (AML)

The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared with single-agent azacitidine. (An event is defined as death or transformation to AML in participants with MDS or CMML, whichever occurs first, and is defined as death in participants …

myelomonocytic leukemia
pevonedistat
chronic myelomonocytic leukemia
myeloid leukemia
induction chemotherapy
Saint John Regional Hospital
 (1.2 away) Contact site
  • 341 views
  • 21 Jul, 2021
  • +319 other locations
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation …

stemi
diabetes
myocardial infarction
stroke
infarct
1240090 - New Brunswick Heart Centre Research Initiative
 (1.2 away) Contact site
  • 1118 views
  • 21 Jul, 2021
  • +3430 other locations
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming …

breast-conserving surgery
erbb2
mastectomy
metastasis
invasive carcinoma
Atlantic Health Sciences Corporation-Saint John Regional Hospital
 (1.2 away) Contact site
  • 591 views
  • 21 Jul, 2021
  • +318 other locations
Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

RATIONALE: Participating in a physical activity program designed to increase free time physical activity and receiving written health education materials may influence the chance of cancer recurring as well as impact on physical fitness, psychological well-being and the quality of life of patients who have undergone surgery and chemotherapy for …

colon cancer
cancer treatment
immunomodulators
x-rays
fatigue assessment and management
Regional Health Authority B, Zone 2
 (1.2 away) Contact site
  • 397 views
  • 23 Jul, 2021
  • +50 other locations
A Phase 3 Efficacy Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer

A study of zolbetuximab (IMAB362) plus mFOLFOX6 versus placebo plus mFOLFOX6 in subjects with Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Why is this study being done? SPOTLIGHT is a new clinical study for adult patients who have any of: advanced unresectable gastric …

Site CA15009
 (1.2 away) Contact site
  • 484 views
  • 23 Jul, 2021
  • +237 other locations
Bentracimab (PB2452) in Ticagrelor-treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure

This is a multi-center, open-label, prospective single-arm study of reversal of the antiplatelet effects of ticagrelor with bentracimab (PB2452) in patients who present with uncontrolled major or life-threatening bleeding or who require urgent surgery or invasive procedure. Approximately 200 patients will be enrolled from approximately 200 centers in North America, …

coronary artery bypass graft
ticagrelor
haemostasis
stroke
blood transfusion
Saint John Regional Hospital
 (1.2 away) Contact site
  • 0 views
  • 21 Jul, 2021
  • +49 other locations
Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)

The purpose of the study is to assess efficacy, safety and tolerability of treatment with zibotentan and dapagliflozin in combination and alone, compared with placebo in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) between 20 and 60 mL/min/1.73^2.

Research site
 (1.2 away) Contact site
  • 0 views
  • 13 Jul, 2021
  • +149 other locations
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth of advanced breast cancer when added to standard therapy (Fulvestrant).

mammogram
estrogen
erbb2
estrogen receptor
metastasis
Regional Health Authority B, Zone 2
 (1.2 away) Contact site
  • 0 views
  • 23 Jul, 2021
  • +13 other locations